151358-48-4

DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research[1][2][3][4][5].

DIM-C-pPhCO2Me is a NR4A1 (Nur77) antagonist th at exhibit potent anticancer activity in pancreaticcolonbreastkidneyand rhabdomyosarcoma cells. DIM-C-pPhCO2Me decreases expression of PAX3-FOXO1A and β1-integrin proteins in Rh30 rhabdomyosarcoma and MDA-MB-231 breast cancer cells. DIM-C-pPhCO2Me inhibits migration of Rh30 and MDA-MB-231 cancer cells.''DIM-C-pPhCO2Me is also known as 1,1-bis(3μ-indolyl)-1-(p-carboxymethylphenyl)methane. In pancreatic and colon cancer cellsDIM-C-pPhCO2Me plays an inhibitory role on cell migration. DIM-C-pPhCO2Me prevents the action of mechanistic target of rapamycin (mTOR) and reduces the multiplication and survival of cancer cells. It stimulates reactive oxygen species (ROS) in various cancer cell lines.

Nur77/NR4A1; IDH1

Store at -20°C

[1] Hedrick E, et al. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One. 2015 Jun 2;10(6):e0128308. DOI:10.1371/journal.pone.0128308
[2] Hedrick E, et al. Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy. Endocr Relat Cancer. 2015 Oct;22(5):831-40. DOI:10.1530/ERC-15-0063
[3] Lacey A, et al. Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma. Mol Cancer Ther. 2018 Dec;17(12):2756-2766. DOI:10.1158/1535-7163.MCT-18-0118
[4] Lacey A, et al. PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1. Cancer Res. 2017 Feb 1;77(3):732-741. DOI:10.1158/0008-5472.CAN-16-1546
[5] Cui P, et al. Deficiency of the Transcription Factor NR4A1 Enhances Bacterial Clearance and Prevents Lung Injury During Escherichia Coli Pneumonia. Shock. 2019 Jun;51(6):787-794. DOI:10.1097/SHK.0000000000001184